Friday, 16 October 2026European Markets

TGS Stock Over 12% Down So Far Today

Loading stream...

(VIANEWS) - Shares of TGS (Oslo Børs Benchmark Index_GI: TGS.OL) fell by a staggering 12.5% to kr138.60 at 14:39 EST on Monday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is dropping 0.02% to kr1,198.70, following the last session's upward trend. This seems, at the moment, a somewhat down trend exchanging session today.

TGS's last close was kr158.40, 22.81% under its 52-week high of kr205.20.

About TGS

TGS ASA provides geoscience data products and services to the oil and gas industry worldwide. The company offers geophysical data, including multi-client seismic data; geological data comprising well data products, and interpretive studies and services; and interpretation products and data integration solutions. It also provides imaging services, which include depth and time imaging; marine, land, and ocean bottom nodes; and transition zone, multi component, and 4D time-lapse processing. The company was formerly known as TGS-NOPEC Geophysical Company ASA and changed its name to TGS ASA in June 2021. TGS ASA was founded in 1981 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TGS has a trailing twelve months EPS of kr5.24.

PE Ratio

TGS has a trailing twelve months price to earnings ratio of 26.45. Meaning, the purchaser of the share is investing kr26.45 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.01%.

Volume

Today's last reported volume for TGS is 784723 which is 97.05% above its average volume of 398226.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TGS's EBITDA is 24.09.

Moving Average

TGS's worth is way below its 50-day moving average of kr167.21 and way below its 200-day moving average of kr156.03.

More news about TGS (TGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com